BresMed at Virtual ISPOR Europe 2020

16–19 November

This year’s theme for ISPOR Europe is “Improving Health: Establishing Incentives and Sharing Value.” While the conference is taking place virtually this year, we’re happy to still be contributing a range of workshops, panels and posters. ISPOR Europe normally provides us the chance to catch up with the people we work with throughout the year, and though this year looks different we’re also still available to chat. Email businessdevelopment@bresmed.com if you’d like to arrange a meeting.

Issue Panel

Date & time Code Title Moderator Panelists
Monday 16 November, 15:00-16:00
(Breakout Session 1)
IP1
Is It Time to Find Greater Efficiencies in HTA for Rare Diseases and Cell and Gene Therapies?
Josie Godfrey
Ron Akehurst, Fleur Chandler, Sachin Kamal-Bahl

Workshops

Date & time Code Title Discussion leaders
On-demand
Why R We Bothering? The Why and How of Using R for Integrated Analysis and Modelling
Lea Trela-Larsen, Raquel Aguiar-Ibáñez, Howard Thom, Rose Hart
Thursday 19 November, 13:00-14:00
(Breakout Session 4)
W7
How to Model the Cost-Effectiveness of Histology-Independent Oncology Therapies within Health Technology Assessments (HTAs)
Raquel Aguiar-Ibáñez, Gianluca Baio, Jacoline Bouvy, Dawn Lee

Podium presentations

Date & time Code Title Moderator Authors
On-demand from
9 November
EX2
Structural Uncertainty in Survival Extrapolation: Exploring the Impact of Four Model Averaging Methods and Adjusting for Data Maturity
Nick Latimer
Hardern C, Lee D, Sly I, Kearns B

Posters

Session Code Title Authors
PCN: Cancer
PCN140
An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal
Guerreiro R, Paquete AT, Iadeluca L, Almond C, Albuquerque de Almeida F, Inês M, Costa J, Borges M, Silva Miguel L
PCN: Cancer
PCN141
Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer- [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination
Vondeling G, Palaka E, Livings C, Naik J, Sullivan W
PCN: Cancer
PCN249
A Review of Consistencies in Decision-Making across Nice Health Technology Assessments of Immune Checkpoint Inhibitors
Hale O, Casson J, Horscroft J, Sullivan W, Kiff C
PCN: Cancer
PCN41
Matching-Adjusted Indirect Treatment Comparisons (MAIC) of the Effect of Lorlatinib Versus Chemotherapy on Overall Survival (OS) and Progression-Free Survival (PFS) for Patients with Second-LINE or Later Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Smith S, Albuquerque de Almeida F, Inês M, Iadeluca L, Cooper M
PCN: Cancer
PCN56
Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece
Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Almond C, Tzanetakos C, Kourlaba G
PMU: Multiple Diseases
PMU112
Context Matters – A Taxonomy of Real-World DATA and Evidence to Support HTA Decision-Making
Murphy L, Mestre-Ferrandiz J, Solà-Morales O, de Pouvourville G, Cunningham D, Corry S, Akehurst R
PNS: No specific disease
PNS132
Did the NICE Technical Engagement Process Deliver More Efficient Decision Making?
Barnes AM, Qu T, Taylor S, Lilley C, Kidd R, Lee D

We’d love to talk with you

Email businessdevelopment@bresmed.com to arrange a meeting

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies